Table 4.
FDA- and EMA-approved FDC products with multilayer technology.
| Product Name | Chemical Name | Dosage Form | Therapeutic | Manufacturer/ Developer |
Ref |
|---|---|---|---|---|---|
| Alprax Plus | Sertraline/ Alprazolam |
Bilayer tablets | Anti-depressant | Torrent Pharmaceuticals Ltd. | [44] |
| Glycomet-GP2Forte | Metformin hydrochloride/Glimepiride | Bilayer tablets | Anti-diabetic | USV Limited | [45] |
| Lopressor HCT | Metoprolol/Hydrochlorothiazide | Bilayer tablets | Antihypertensive | Novartis Pharmaceuticals Corporation | [46] |
| Diovan HCT | Valsartan/ Hydrochlorothiazide |
Bilayer tablets | Antihypertensive | Novartis Pharmaceuticals Corporation | [47] |
| Lotensin HCT | Benazepril/Hydrochlorothiazide | Bilayer tablets | Antihypertensive | Novartis Pharmaceuticals Corporation | [48] |
| Clarinex-D | Desloratadine/Pseudoephedrine sulphate | Bilayer tablets | Allergic rhinitis | MSD | [49] |
| Treximet | Sumatriptan/Naproxen sodium | Bilayer tablets | Migraine | Pernix Therapeutics | [50] |
| Atripla | Efavirenz/Emtricitabine/Tenofovir disoproxil fumarate | Multilayer tablets | HIV/AIDS | Gilead Sciences | [51] |
| Under development -In clinical trials/Patent EP 2 682 112 A1 |
Flurbiprofen 100 mg Famotidine 20 mg | Multilayer tablet | An NSAID with anti-inflammatory, analgesic and antipyretic activities, an H2 receptor antagonist used for preventing or minimizing gastroin-testinal side effects caused by NSAIDs | Pharmaceutical Research Unit, Jordan | [52] |